IonQ and the Centre for Commercialization of Regenerative Medicine (CCRM) have established a strategic investment partnership to accelerate the development of next-generation therapeutics utilizing hybrid quantum and quantum-AI technologies. This collaboration designates IonQ as the core quantum technology partner across CCRM’s global network of advanced therapy hubs, including over 100,000 square feet of good manufacturing practice (GMP) facilities and a team of 300+ scientific staff. Initial projects, slated to launch in Canada and Sweden in 2026, will focus on areas like bioprocess optimization and disease-modeling workflows, aiming to revolutionize medicine and deliver durable treatments for chronic diseases.
IonQ and CCRM Strategic Quantum-Biotech Collaboration
IonQ and the Centre for Commercialization of Regenerative Medicine (CCRM) announced a strategic collaboration in December 2025. This partnership aims to accelerate the development of advanced therapeutics using hybrid quantum and quantum-AI technologies. IonQ will serve as a core technology partner across CCRM’s global network of advanced therapy hubs, and will also make an investment into CCRM’s new quantum-biotech initiatives. CCRM brings over 100,000 square feet of GMP facilities and 300+ scientific staff to the collaboration.
The initial focus of this partnership will be on areas like bioprocess optimization, disease-modeling workflows, and quantum-enhanced simulation for designing and manufacturing advanced therapies. Projects are slated to launch in both Canada and Sweden in 2026. This collaboration leverages CCRM’s expertise in regenerative medicine with IonQ’s leadership in quantum technologies, with the goal of addressing critical challenges in healthcare and life sciences.
This partnership builds on IonQ’s existing collaborations, including work with AstraZeneca in Sweden and partnerships in Switzerland and South Korea. IonQ’s technology, including systems like IonQ Forte and IonQ Forte Enterprise, has demonstrated results – achieving 99.99% two-qubit gate fidelity in 2025. The company intends to deliver a quantum computer with 2 million qubits by 2030, expanding its impact on areas like drug discovery and materials science.
CCRM’s Regenerative Medicine Network and Expertise
CCRM and IonQ have established a strategic partnership to accelerate the development of advanced therapeutics using quantum and quantum-AI technologies. IonQ will serve as the core technology partner across CCRM’s global network of advanced therapy hubs, investing in CCRM’s new quantum-biotech initiatives. CCRM, established in 2011, operates with over 100,000 square feet of GMP facilities and a team of 300+ scientific staff, positioning it as a leading accelerator in the field of advanced therapies.
This collaboration will initially focus on areas like bioprocess optimization, disease-modeling workflows, and quantum-enhanced simulation to improve the design and manufacturing of advanced therapies. Projects are slated to launch in both Canada and Sweden in 2026. CCRM Nordic will play a key role, as Sweden, like Canada, prioritizes the development and commercialization of both advanced therapies and quantum computing.
IonQ’s quantum technologies aim to reshape healthcare, with the company achieving 99.99% two-qubit gate fidelity in 2025 – a world record in quantum computing performance. The partnership builds on IonQ’s existing collaborations with AstraZeneca and Einride in Sweden, and expands its European presence with innovation centers in Switzerland and operations in multiple countries including the UK, South Korea, and Canada.
IonQ’s Quantum Technology and Global Expansion
IonQ is collaborating with the Centre for Commercialization of Regenerative Medicine (CCRM) to advance therapeutic development using quantum and quantum-AI technologies. This partnership involves an investment into CCRM’s quantum-biotech initiatives, establishing IonQ as a core technology partner within CCRM’s global network. Initial projects, launching in Canada and Sweden in 2026, will focus on areas like bioprocess optimization, disease-modeling, and quantum-enhanced simulation to improve advanced therapy design and manufacturing.
IonQ’s global expansion includes recent collaborations and acquisitions demonstrating its commitment to quantum technology leadership. Beyond the CCRM partnership, IonQ established a quantum application development center with AstraZeneca in Sweden and expanded R&D through the acquisition of Oxford Ionics. Further, IonQ established European Innovation Centers in Switzerland and Sweden, and has operations in locations including the United Kingdom, South Korea, and the United States.
IonQ’s quantum computers, including the IonQ Forte and IonQ Forte Enterprise, have demonstrated significant performance, achieving 20x results for customers like Amazon Web Services and AstraZeneca. In 2025, the company reached 99.99% two-qubit gate fidelity, a world record in quantum computing. IonQ aims to deliver a quantum computer with 2 million qubits by 2030, supporting advancements in fields like drug discovery and materials science.
Just as CCRM focused on biomanufacturing 15 years ago, this frontier-of-science collaboration will help accelerate the discovery and application of advanced therapies, with the potential to make a real difference for patients worldwide.
Michael May, President and CEO of CCRM
Applications in Advanced Therapy Development
IonQ and the Centre for Commercialization of Regenerative Medicine (CCRM) have partnered to accelerate advanced therapy development using quantum and quantum-AI technologies. This collaboration includes an investment into CCRM’s quantum-biotech initiatives, establishing IonQ as a core technology partner within CCRM’s global network of advanced therapy hubs. Initial projects, launching in Canada and Sweden in 2026, will focus on areas like bioprocess optimization, disease modeling, and quantum-enhanced simulation to improve therapeutic manufacturing.
CCRM, with over 100,000 square feet of GMP facilities and 300+ scientific staff, is a leading accelerator in advanced therapies established in 2011. This partnership aims to address challenges in healthcare and life sciences by combining CCRM’s expertise in next-generation therapeutics with IonQ’s quantum technology. IonQ’s advancements, including achieving 99.99% two-qubit gate fidelity in 2025, position them to deliver a 2 million qubit system by 2030.
This collaboration builds on existing partnerships for IonQ, including work with AstraZeneca in Sweden and Einride in Stockholm. IonQ’s technology has already demonstrated 20x performance results with partners like Amazon Web Services and NVIDIA. The partnership intends to leverage these advancements to revolutionize medicine and provide computational advantages for CCRM’s global network of researchers, industry partners, and investors.
